Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-05-30
DOI
10.1038/s41598-018-26904-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study
- (2018) Xavier Sáez-Llorens et al. LANCET INFECTIOUS DISEASES
- A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice
- (2018) Viswanathan Ramasamy et al. PLoS Neglected Tropical Diseases
- Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo
- (2018) Rahul Shukla et al. Frontiers in Microbiology
- Major findings and recent advances in virus–like particle (VLP)-based vaccines
- (2017) Mona O. Mohsen et al. SEMINARS IN IMMUNOLOGY
- Immune correlates of protection for dengue: State of the art and research agenda
- (2017) Leah C. Katzelnick et al. VACCINE
- Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?
- (2017) Stephen S. Whitehead et al. Cold Spring Harbor Perspectives in Biology
- In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
- (2017) Stephen S. Whitehead et al. PLoS Neglected Tropical Diseases
- DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection
- (2017) Jose L. Slon Campos et al. PLoS One
- Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies
- (2016) Niyati Khetarpal et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies
- (2016) Ankur Poddar et al. BMC BIOTECHNOLOGY
- Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort
- (2016) Leah C. Katzelnick et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment
- (2016) Neil M. Ferguson et al. SCIENCE
- Protective and immunological behavior of chimeric yellow fever dengue vaccine
- (2016) Scott B. Halstead et al. VACCINE
- Immune correlates for dengue vaccine development
- (2015) Anon Srikiatkhachorn et al. Expert Review of Vaccines
- Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site
- (2015) Scott A. Smith et al. JOURNAL OF VIROLOGY
- Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice
- (2015) Satoru Watanabe et al. JOURNAL OF VIROLOGY
- Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
- (2015) Sri Rezeki Hadinegoro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
- (2015) Luis Villar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells
- (2015) Amporn Suphatrakul et al. VACCINE
- Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
- (2015) Lav Tripathi et al. Frontiers in Microbiology
- Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
- (2014) Maria Rosario Capeding et al. LANCET
- Functional Analysis of Antibodies against Dengue Virus Type 4 Reveals Strain-Dependent Epitope Exposure That Impacts Neutralization and Protection
- (2013) S. Sukupolvi-Petty et al. JOURNAL OF VIROLOGY
- The global distribution and burden of dengue
- (2013) Samir Bhatt et al. NATURE
- Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies
- (2013) Shailendra Mani et al. PLoS One
- The Economic Burden of Dengue
- (2012) Duane J. Gubler AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Evaluation of Extracellular Subviral Particles of Dengue Virus Type 2 and Japanese Encephalitis Virus Produced by Spodoptera frugiperda Cells for Use as Vaccine and Diagnostic Antigens
- (2010) M. Kuwahara et al. Clinical and Vaccine Immunology
- Dengue vaccines: state of the art
- (2010) Sathyamangalam Swaminathan et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris
- (2010) Gaurav Batra et al. JOURNAL OF BIOSCIENCE AND BIOENGINEERING
- Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3
- (2010) James D. Brien et al. JOURNAL OF VIROLOGY
- Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
- (2010) W. Dejnirattisai et al. SCIENCE
- Immature Dengue Virus: A Veiled Pathogen?
- (2010) Izabela A. Rodenhuis-Zybert et al. PLoS Pathogens
- Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses
- (2010) Wahala M. P. B. Wahala et al. PLoS Pathogens
- The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1
- (2010) Bimmi Shrestha et al. PLoS Pathogens
- Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins
- (2009) Pei-Gang Wang et al. PLoS One
- Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties
- (2009) Wenquan Liu et al. VIRUS GENES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started